Last reviewed · How we verify
Adalimumab subcutaneous injection
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Psoriasis.
At a glance
| Generic name | Adalimumab subcutaneous injection |
|---|---|
| Sponsor | Biocad |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TNF-α is a key pro-inflammatory cytokine that drives inflammation in autoimmune and inflammatory diseases. By blocking TNF-α, adalimumab suppresses the inflammatory cascade, reducing immune cell activation and tissue damage. This mechanism is effective across multiple inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Psoriasis
- Ankylosing spondylitis
- Polyarticular juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Opportunistic infections
- Malignancy risk
Key clinical trials
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
- Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD (PHASE2)
- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab (PHASE3)
- An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis (PHASE2)
- Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial (NA)
- Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (PHASE3)
- Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab subcutaneous injection CI brief — competitive landscape report
- Adalimumab subcutaneous injection updates RSS · CI watch RSS
- Biocad portfolio CI